Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 12, 2015, Pages 4425-4433

  Pramfalk, Camilla ^a   Pavlides, Michael ^a,b   Banerjee, Rajarshi ^a   McNeil, Catriona A ^a   Neubauer, Stefan ^a   Karpe, Fredrik ^a,c   Hodson, Leanne ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; APOLIPOPROTEIN B; CARBON DIOXIDE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRACER; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; FAT INTAKE; FATTY ACID; LIPID; PALMITIC ACID DERIVATIVE;

ADULT; AGE; ARTICLE; BODY COMPOSITION; BODY MASS; DIET RESTRICTION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; HUMAN; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BIOSYNTHESIS; BLOOD; FAT INTAKE; GENETICS; LIPID METABOLISM; LIPOGENESIS; LIVER; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; POSTPRANDIAL STATE; SEXUAL DEVELOPMENT;

3-HYDROXYBUTYRIC ACID; ADULT; AGED; CARBON DIOXIDE; DIETARY FATS; FASTING; FATTY ACIDS; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; LIPOGENESIS; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; PALMITATES; POSTPRANDIAL PERIOD; SEX CHARACTERISTICS; TRIGLYCERIDES;

EID: 84951160663     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2649     Document Type: Article

References (45)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. 4.
4. Graff M, North KE, Franceschini N, et al. PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI family heart study. Int J Obes (Lond). 2013; 37:432-438.
5. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28: 1225-1236.
6. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-431.
7. Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it?s not just about sex hormones. J Clin Endocrinol Metab. 2011;96:885-893.
8. Nielsen S, Karpe F. Determinants of VLDL-triglycerides production. Curr Opin Lipidol. 2012;23:321-326.
9. Hodson L, Bickerton AS, McQuaid SE, et al. The contribution of splanchnic fat to VLDL triglyceride is greater in insulin-resistant than insulin-sensitive men and women: studies in the postprandial state. Diabetes. 2007;56:2433-2441.
10. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726-735.
11. Hodson L, Frayn KN. Hepatic fatty acid partitioning. Curr Opin Lipidol. 2011;22:216-224.
12. Marinou K, Adiels M, Hodson L, Frayn KN, Karpe F, Fielding BA. Youngwomenpartition fatty acids towards ketone body production rather than VLDL-TAG synthesis, compared with young men. Br J Nutr. 2011;105:857-865.
13. Halkes CJ, van Dijk H, Verseyden C, et al. Gender differences in postprandial ketone bodies in normolipidemic subjects and in untreated patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2003;23:1875-1880.
14. Lifestyles Statistics Team, Health and Social Care Information Centre. Statistics on Obesity, Physical Activity, and Diet. 2015 ed. England United Kingdom: HaSCI Centre. 2015.
15. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15:665-674.
16. Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125: 386-402.
17. Tan GD, Neville MJ, Liverani E, et al. The in vivo effects of the Pro12Ala PPAR-2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia. 2006;49: 158-168.
18. Hodson L, Harnden K, Banerjee R, et al. Lower resting and total energy expenditure in postmenopausal compared with premenopausal women matched for abdominal obesity. J Nutr Sci. 2014;3:e3.
19. Hodson L, McQuaid SE, Karpe F, Frayn KN, Fielding BA. Differences in partitioning of meal fatty acids into blood lipid fractions: a comparison of linoleate, oleate, and palmitate. Am J Physiol Endocrinol Metab. 2009;296:E64-E71.
20. McNeil CA, Pramfalk C, Humphreys SM, Hodson L. The storage stability and concentration of acetoacetate differs between blood fractions. Clin Chim Acta. 2014;433C:278-283.
21. Lund E, Sisfontes L, Reihner E, Bjorkhem I. Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand J Clin Lab Invest. 1989;49:165-171.
22. Lutjohann D, Bjorkhem I, Beil UF, von Bergmann K. Sterol absorption and sterol balance in phytosterolemia evaluated by deuteriumlabeled sterols: effect of sitostanol treatment. J Lipid Res. 1995;36: 1763-1773.
23. van der Hoorn J, Linden D, Lindahl U, et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE. 3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol. 2011;162:1553-1563.
24. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest. 2006;36:98-104.
25. Bergouignan A, Schoeller DA, Votruba S, Simon C, Blanc S. The acetate recovery factor to correct tracer-derived dietary fat oxidation in humans. Am J Physiol Endocrinol Metab. 2008;294:E645-E653.
26. Semple RK, Sleigh A, Murgatroyd PR, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119:315-322.
27. Santoro N, Caprio S, Pierpont B, Van Name M, Savoye M, Parks EJ. Hepatic de novo lipogenesis in obese youth is modulated by a common variant in the GCKR gene. J Clin Endocrinol Metab. 2015; 100:E1125-E1132.
28. Herrema H, Meissner M, van Dijk TH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptorand liver X receptor-controlled metabolic pathways in mice. Hepatology. 2010;51:806-816.
29. Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr. 1998;80:495-502.
30. TimlinMT,Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr. 2005;81:35-42.
31. Diamant YZ, Neuman S, Shafrir E. Effect of chorionic gonadotropin, triamcinolone, progesterone and estrogen on enzymes of placenta and liver in rats. Biochim Biophys Acta. 1975;385:257-267.
32. Paquette A, Wang D, Jankowski M, Gutkowska J, Lavoie JM. Effects of ovariectomy on PPAR-, SREBP-1c, and SCD-1 gene expression in the rat liver. Menopause. 2008;15:1169-1175.
33. Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology. 2004;145:1842-1848.
34. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003;29:478-485.
35. Mancina RM, Matikainen N, Maglio C, et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J Clin Endocrinol Metab. 2015;100: E821-E825.
36. Axelson M, Bjorkhem I, Reihner E, Einarsson K. The plasma level of 7-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7-hydroxylase in man. FEBS Lett. 1991;284:216-218.
37. Sarac I, Backhouse K, Shojaee-Moradie F, et al. Gender differences in VLDL1 and VLDL2 triglyceride kinetics and fatty acid kinetics in obese postmenopausal women and obese men. J Clin Endocrinol Metab. 2012;97:2475-2481.
38. McGarry JD, Mannaerts GP, Foster DW. A possible role for malonyl- CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest. 1977;60:265-270.
39. Knuth ND, Horowitz JF. The elevation of ingested lipids within plasma chylomicrons is prolonged in men compared with women. J Nutr. 2006;136:1498-1503.
40. Roberts R, Bickerton AS, Fielding BA, et al. Reduced oxidation of dietary fat after a short term high-carbohydrate diet.AmJ Clin Nutr. 2008;87:824-831.
41. Magkos F, Patterson BW, Mohammed BS, Klein S, Mittendorfer B. Women produce fewer but triglyceride-richer very low-density lipoproteins than men. J Clin Endocrinol Metab. 2007;92:1311-1318.
42. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.JAMA. 2007;298:299-308.
43. Parini P, DavisM,Lada AT, et al.ACAT2is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation. 2004;110:2017-2023.
44. AlgerHM,Brown JM, Sawyer JK, et al. Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol- associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem. 2010;285:14267-14274.
45. Parini P, Jiang ZY, Einarsson C, et al. ACAT2 and human hepatic cholesterol metabolism: identification of important gender-related differences in normolipidemic, non-obese Chinese patients. Atherosclerosis. 2009;207:266-271.